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Increased preoperative inflammation scores, such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR)
and inflammation-based index (IBI) have been related to post-transplant HCC recurrence. We evaluated the association
between inflammation-based scores (NLR, PLR, IBI) and post-LT HCC recurrence as well as tumor necrosis after transarterial
embolization. 150 consecutive patients who underwent transplantation for HCC within the Milan criteria between 1996 and
2010 were included; data regarding inflammatory markers, patient and tumor characteristics were analyzed. NLR, PLR, and
IBI were not significantly associated with post-LT HCC recurrence or worse overall survival. Increased NLR and PLR were
associated with complete tumor necrosis in the subset of patients who received preoperative transarterial embolization
(P< 0.05). Cox regression analysis revealed that absence of neoadjuvant transarterial therapy (OR5 4.33, 95% CI51.28-
14.64; P50.02) and no fulfillment of the Milan criteria in the explanted liver (OR5 3.34, 95% CI51.08-10.35; P50.04) were
independently associated with post-LT HCC recurrence inflammation-based scores did not predict HCC recurrence post-LT in
our group of patients. NLR and PLR were associated with better response to TAE, as this was recorded histologically in the
explanted liver. Histological fulfillment of the Milan criteria and absence of neoadjuvant transarterial treatment were signifi-
cantly associated with post-LT HCC recurrence. Liver Transpl 20:1327-1335, 2014. VC 2014 AASLD.
Received January 29, 2014; accepted July 2, 2014.
Hepatocellular carcinoma (HCC) is the fifth most fre-
quently diagnosed cancer and the third cause of
cancer-related mortality worldwide.1 Current manage-
ment depends on the HCC stage at diagnosis and con-
sists of hepatic resection, liver transplantation (LT),
radiofrequency ablation, transarterial embolization
(TAE)/transarterial chemoembolization (TACE), or sys-
temic therapy.2 Patients with tumors within the Milan
criteria, ie, up to 3 lesions of 3 cm or a solitary lesion
of maximum diameter 5 cm, are potential candidates
for LT.3 Currently, 14% of liver transplants in the
United Kingdom are performed as treatment for HCC.4
Tumor recurrence is an unfavorable outcome
that occurs in approximately 20% of transplanted
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patients.5 The main limitation of Milan criteria is that
currently they use a solely radiological evaluation of
tumor size and number and do not take into account
tumor biological or immunological factors. The latter
2 factors, if validated as preoperative risk factors for
cancer relapse, would help to refine the selection of
appropriate LT candidates.
Predictive factors of recurrence are currently not well
established. Summation of all nodule diameters or total
volume of nodules, the absence of neoadjuvant transarte-
rial therapy, the level of a-fetoprotein (AFP), and reduced
exposure to calcineurin inhibitors in the first month post
LT are some of the factors related to HCC recurrence, but
these are not universally reproducible.6-9 Chronic sys-
temic inflammation has been linked with several human
cancers, including HCC, and is associated with poor out-
come.10 Proposed inflammatory scores, such as neutro-
phil to lymphocyte ratio (NLR), platelet to lymphocyte
ratio (PLR), inflammation-based index (IBI), and Glasgow
prognostic score (GPS), are associated with survival in
HCC11,12 and other cancers.11,13,14 These scores are
increased in patients with advanced HCC and are predic-
tors of poor prognosis.15 Moreover, they have been asso-
ciated with high risk of tumor recurrence in colorectal,
breast, and other malignancies.14 The aim of this study
was to evaluate the association of NLR, PLR, and IBI with
posttransplant HCC recurrence in consecutive patients
transplanted for HCC within Milan criteria, based on
radiological imaging.
PATIENTS AND METHODS
Patients
One hundred fifty consecutive patients from our pro-
spectively compiled database who underwent liver
transplantation for HCCs in the Royal Free Hospital
between 1996 and 2010 were included in the study,
as previously described.9 Patients were listed if they
were within the Milan criteria based on radiological
imaging. Incidental HCCs in the explanted liver were
also included in the study (n519). All patients after
2001 were offered TAE as a bridging treatment pre-LT
if there were no contraindications and on an individ-
ual basis before this time, based on physicians’ pref-
erence. TAE was contraindicated in patients with
advanced liver disease (Child-Pugh score more than 8)
and/or clinically evident ascites. TAE was performed
with selective angiography, with a subsequent emboli-
zation using polyvinyl alcohol (PVA) particles as the
embolizing agent. The diameter of PVAs was 40-150
lm after 2005 and 100-500 lm before then. A proto-
col computed tomography (CT) scan was performed 1
month after TAE, and subsequent treatments were
decided upon according to residual vascularity. A
subset of patients was randomized to TACE between
2003 and 2010 as part of a clinical trial.16 Eighteen
patients who eventually underwent transplantation
were randomized, 9 being allocated in the TACE (with
cisplatin) group and 9 in the TAE group. In the trial
no significant difference in survival between the 2
therapies was demonstrated.16 No patient had TAE/
TACE in the month before LT.
All patients had protocol imaging studies [CT or
magnetic resonance imaging (MRI)] while on the
transplant waiting list every 3 months until LT, for
the evaluation of potential HCC progression. Chest
and liver CT were performed as a standard protocol in
all patients after LT every 6 months in order to diag-
nose tumor recurrence. All patients undergoing trans-
plantation were followed up at least once every 6
months, until death or completion of study.
Histopathologic evidence of tumor necrosis after
transarterial therapy was evaluated in the explanted
livers and classified as follows: (1) complete necrosis,
in which only necrotic material and no viable cancer
cells were visible; (2) partial necrosis, in which both
necrotic material and residual tumor were identified;
and (3) no necrosis, in which tumor was identified
with no evidence of necrotic material. All tumor
lesions were measured and compared with the latest
pre-LT radiological findings. Any discrepancy between
the two was recorded.
Laboratory variables, including full blood count, ala-
nine aminotransferase, aspartate aminotransferase,
bilirubin, alkaline phosphatase, albumin, prothrom-
bin time, and AFP were collected on the day of
transplantation.
Inflammation-based Scores
NLR, PLR, and IBI were the inflammation-based
scores evaluated in the study. NLR is the calculated
ratio of blood neutrophil to lymphocyte count. PLR is
calculated by dividing the absolute platelet count by
the absolute lymphocyte count. IBI is a score that
combines C-reactive protein (CRP) and serum albu-
min. Patients with a CRP 10 mg/dL and hypoalbu-
minemia (serum albumin was<35 g/L) are allocated
a score of 2; those with either one of the above-
mentioned abnormalities have a score of 1, whereas
patients with normal values (CRP was <10 mg/dL,
albumin was 35 g/L) are allocated a score of 0.
These scores were calculated individually for every
patient by laboratory values collected at 3 different
time points, the day of their elective admission for LT
and 1 month and 6 months after LT. There was no
active infection (including positive bacterial cultures,
antibiotic treatment for clinical suspicion of infection,
or HIV positivity) in any of the patients who were
included in the study.
Statistical Analysis
All data were analyzed in the statistical package SPSS
(version 22.0; IBM, New York, NY). Comparisons of
continuous variables between or among groups were
made by t test and analysis of variance when quanti-
tative variables were normally distributed. Distribu-
tion of nonparametric continuous variables in
different groups was analyzed by Mann-Whitney or
Kruskal-Wallis test. Qualitative data were compared
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with corrected chi square or 2-tailed Fisher’s exact
test. Multivariate analysis used Cox regression.
P<0.05 was considered statistically significant.
RESULTS
Patient Characteristics
Between 1996 and 2010, 150 consecutive patients with
HCC underwent transplantation and were included in
the study. The predominant causes of chronic liver dis-
ease were chronic hepatitis C (40% of patients), chronic
hepatitis B (23%) and alcohol abuse (13%). Mean age of
the study population was 5467 years, and 125 (83%)
were males. Mean Child-Pugh score was 762. Seventy-
one patients (47%) had transarterial embolization prior
to LT. Thirteen patients (9%) had an AFP >200 ng/mL.
Median time on the waiting list was 1.6 (range50-12)
months, and median follow-up time was 28 (range50-
116) months (Table 1).
Tumor Characteristics
Among the 150 patients included in the study, 107
(72%) fit the Milan criteria based on histopathological
examination of the explanted liver. Thus, there was a
28% discrepancy between radiological and histological
evaluation. In 19 patients, HCC was an incidental
finding. Twelve patients (8%) had a poorly differenti-
ated HCC, whereas microvascular invasion was found
in 26%. Nineteen patients (13%) had an HCC recur-
rence. Median time to recurrence was 29 (range54-
63) months. Two patients had a late HCC recurrence,
one at 54 months and the other at 63 months post-
transplantation. Because these tumors appeared in
noncirrhotic livers, we classified them as recurrences
rather than de novo tumors.
Complete necrosis was found in 22 of 71 (31%)
explanted tumors in patients treated with TAE or TACE
versus 54% with partial and 15% with no necrosis. All
patients with complete necrosis did not have HCC
recurrence at the completion of the follow-up.
Inflammation Characteristics
Median NLR of the study population was 2.2
(range51-14) on the day of liver transplantation, 4.8
(range51-43) 1 month post-LT, and 2.5 (range50.5-
29) 6 months post-LT. Nineteen patients (13%) had an
TABLE 1. Patient Characteristics
Number of patients 150
Median follow-up (months) 28 (range50-116)
Mean age (years) 5467
Etiology of liver disease, n (%)
Hepatitis C virus 60 (40)
Hepatitis B virus 34 (23)
Alcohol 20 (13)
Unknown 36 (24)
Sex male, n (%) 125 (83)
Mean Child-Pugh score 762
Median AFP (ng/mL) 13 (range52-67,380)
AFP >200 ng/mL, n (%) 13 (9)
TACE/TAE, n (%) 71 (47)
Median time on waiting list (months) 1.6 (range50-12)
HCC recurrence yes, n (%) 19 (13)
Median time to recurrence (months) 29 (range54-63)
Median NLR pre-LT 2.2 (range 51-14)
Median NLR at month 1 post-LT 4.8 (range51-43)
Median NLR at month 6 post-LT 2.5 (range50.5-29)
NLR 5 pre-LT, n (%) 19 (13)
NLR 5 at month 1 post-LT, n (%) 63/128 (49)
NLR 5 at month 6 post-LT, n (%) 10/91 (11)
Median PLR pre-LT 68 (range510-681)
Median PLR at month 1 post-LT 213 (range532-1120)
Median PLR at month 6 post-LT 135 (range525-1280)
PLR 150 pre-LT, n (%) 17 (11)
PLR 150 at month 1 post-LT, n (%) 89/128 (69)
PLR 150 at month 6 post-LT, n (%) 36/90 (40)
CRP (mg/dL) 6 (range51-80)
IBI score pre-LT, n (%) 0:35 (35.4); 1:46 (46); 2:18 (19)
IBI score at month 1 post-LT, n (%) 0:4 (4.5); 1:59 (65.5); 2:27 (30)
IBI score at month 6 post-LT, n (%) 0: 1(3); 1: 36 (78); 2: 9 (19)
NOTE: Continuous variables are expressed as mean6 standard deviation when distribution is normal. Nonparametric con-
tinuous variables are expressed as median and range. Categorical variables are described as n (%).
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NLR 5 before LT, which has been used as a cutoff in
other studies to predict tumor recurrence and worse
outcome.17
Median PLR was 68 (range510-681) preoperatively.
This was markedly increased on subsequent measure-
ments, to 213 (range532-1120) at 1 month and 135
(range525-1280) at 6 months post-LT. PLR 150,
which is a cutoff value previously associated with vas-
cular invasion,18 was found in 17 patients (11%) out
of 128 the day of transplantation. Eighty-nine
patients (69.5%) had a PLR 150 at 1 month after LT,
and 36/90 (40%) patients had an elevated PLR 6
months after LT.
A normal IBI score was found in 35 out of 99
(35.4%) patients before LT; 46 patients had 1 abnor-
mal parameter (scoring 1), and 18 patients out of 99
(19%) had both albumin and CRP above the normal
range (IBI score of 2). Median CRP at the same time
point was 6 (range51-80) mg/dL. Conversely, only 4
patients had a normal IBI score 1 month post-LT; 59
had a score of 1, and 30% had 2 abnormal parame-
ters. Abnormality of IBI persisted 6 months post-LT;
only 1% scored 0. Median CRP was 16.5 (range51-
220) mg/dL and 4 (range51-189) at the 1st and 6th
months post-LT, respectively (Table 1).
Inflammatory Scores as Predictors of HCC
Recurrence and Survival
In our cohort of patients, NLR was not associated
with post-LT HCC recurrence at any of the 3 different
time points when it was measured (P50.08 before LT,
P50.74 1 month post-LT, P50.09 6 months post-LT;
Fig. 1). The correlation of an elevated NLR 5 with
cancer relapse did not reach statistical significance
(P50.47, P50.42, and P51.00 at LT and at 1 and 6
months after, respectively). Moreover, NLR was not
significantly different between patients who had TAE/
TACE and those who did not (P50.1). Distribution of
PLR was not significantly different between patients
with recurrence and those without (P50.63 at LT,
P50.24 1 month post-LT, P50.15 6 months post-LT;
Fig. 2). CRP, serum albumin, and calculated IBI score
were not predictive of HCC recurrence on univariate
analysis. In particular, no patient with the highest IBI
score of 2 at LT experienced an HCC recurrence.
Additionally, neither neutrophils nor lymphocytes
were found to be significantly different between
patients who experienced an HCC recurrence and
those who did not (Table 2).
NLR was equally distributed in patients who
underwent transplantation within or outside the
Milan criteria (P50.72). Moreover, there was no sig-
nificant association between total tumor size or
number and elevated NLR (P50.59 and P50.94
respectively). Inflammation-based scores pre-LT
were compared to response to transarterial neoadju-
vant therapy as this was assessed by histology in
the explanted liver. Median NLR was 1.5 (range5
0.7-4), 2.5 (range50.7-14), and 2.8 (range50.8-12)
in patients with no, partial, and complete necrosis
after TAE, respectively (P50.03; Fig. 3). When the
analysis was repeated with a cutoff NLR value of 5,
there was no significant difference (P50.25). Lym-
phocytes were not associated with the difference in
NLR; they were distributed homogeneously between
patients who responded to TAE and nonresponders
(P50.7). There were significantly more neutrophils
in patients who completely responded to TAE com-
pared with those with partial and no response
(P50.03).
The same pattern appeared in the analysis of PLR
compared with no, partial, or complete tumor necro-
sis. Increased PLR was significantly associated with
complete tumor necrosis after TAE on univariate anal-
ysis (P50.02). Platelets were significantly increased
in TAE responders compared with partial responders
Figure 1. NLR was not significantly different between patients
with and without HCC recurrence (median NLR 1.6 and 2.3,
respectively; P50.08).
Figure 2. PLR was not significantly different between patients
with and without HCC recurrence (median PLR 66 and 70,
respectively; P50.63).
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or nonresponders (P50.03). IBI was not associated
with response to TAE, nor were CRP and serum albu-
min (P50.72, P50.33, and P50.79, respectively).
Moreover, NLR and PLR at 1 and 6 months post-LT
were not associated with tumor necrosis in patients
treated preoperatively with TAE (data shown in
Table 2).
Inflammatory scores were also analyzed to detect
any association with overall survival of our cohort,
but no score was significantly associated with sur-
vival. Preoperative NLR 5 did not predict worse sur-
vival (P50.88), nor did PLR 150 (P50.64) or high
IBI (P50.15). To avoid any selection bias, statistical
analysis was repeated after exclusion of patients who
died within 1 month of LT (n56), and results did not
substantially change (data not shown).
Predictors of HCC Recurrence
On univariate analysis, post-LT HCC recurrence was
associated with tumor outside the Milan criteria histo-
logically (P50.001), summation of total diameter
either histologically or radiologically of tumor nodules
(P50.002 and P50.009 respectively), diameter of the
largest nodule either radiologically or histologically
(P50.001 both), no transarterial embolization
(P50.009), absence of histological response to TAE
(P50.002), microvascular and macrovascular inva-
sion (P50.048 and P50.046, respectively), and pre-
LT value of AFP >200 ng/mL (P50.003). Tumor
grade and presence of multifocal or satellite nodules
were not associated with HCC recurrence (P50.13,
P50.62, and P50.2, respectively).
To correct for the different policies regarding TAE
over time, the period before and after 2001 was
entered in the multivariate analysis as a binary
variable. On Cox regression analysis, absence of neo-
adjuvant transarterial therapy (OR54.33, 95% CI5
1.28-14.64; P50.02) and no fulfillment of the Milan
criteria in the explanted liver (OR53.34, 95% CI5
1.08-10.35; P50.04) were the independent predictors
of post-LT HCC recurrence. Results did not substan-
tially change when the analysis was performed after
exclusion of incidental HCCs in the explanted liver or
after the exclusion of patients who died within 1
month from LT (n56).
DISCUSSION
The main finding of our study was that inflammation-
based scores were not associated with HCC recur-
rence after LT. This finding is in contrast to the
majority of similar previously published studies,
which have associated such scores with HCC relapse
and/or worse overall survival.11,12,17,19,20
To date, inflammatory markers and particularly
inflammation-based scores have been described as
TABLE 2. Univariate Analysis of Inflammation Scores as Predictors of HCC Recurrence Based on 150 Patients
HCC Recurrence No Recurrence P Value
Patients, n (%) 19 (13) 131 (87)
Median NLR pre-LT 1.6 (range50.4-5) 2.3 (range51-14) 0.08
NLR 5 pre-LT, n (%) 1 (5) 18 (13.7) 0.47
Median PLR pre-LT 66 (range520-156) 70 (range510-681) 0.63
PLR 150 pre-LT, n (%) 1 (5) 16 (12) 0.47
Median CRP (mg/dL) 3 (1-80) 7 (range 1-77) 0.18
Median neutrophils count (3103/mL) 1.9 (range50.7-6.4) 2.6 (range50.5-8) 0.1
Median lymphocytes count (3103/mL) 0.9 (range50.4-3.1) 1.1 (range5 0.1-6.9) 0.74
IBI score, n (%) 0:4 (33); 1:8 (66) 0:31 (35); 1:38 (43); 2:18 (20) 0.16
Median NLR at month 1 post-LT 6 (range52.5-14.3) 4.7 (range51-43) 0.74
Median NLR at month 6 post-LT 3 (range 51.8-6.4) 2.5 (range50.5-29) 0.09
Median PLR at month1 post-LT 279 (range589-594) 211 (range532-1120) 0.24
Median PLR at month 6 post-LT 155 (range5120-286) 130 (range525-1280) 0.15
NOTE: Nonparametric continuous variables are expressed as median (range). Categorical variables are expressed as n (%).
Figure 3. NLR was significantly higher in patients with com-
plete necrosis post-TACE/TAE versus those with partial or no
necrosis (median NLR 2.8, 2.5, and 1.5 respectively; P50.03).
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predictors of cancer-related prognosis and survival in
several malignancies, such as colorectal, breast, lung,
and gastric cancers.14,21,22 The theoretical back-
ground for the possible predictive value of these
markers lies in the close association of chronic
inflammation and carcinogenesis. Host responses via
innate and adaptive immune systems may result in a
worse prognosis of HCC. CD8 T cells and natural
killer cells are protective against tumor proliferation,
and these are decreased in HCC.23 In contrast,
increased intratumor CD66b1 neutrophils have been
identified independently with poor HCC outcome.24
NLR has been analyzed most often quantitatively,
but also several cutoff values have been described as
predictors of worse cancer prognosis. Predominantly,
a cutoff NLR 5 was associated with worse HCC out-
come and survival.17 NLR in HCC was first evaluated
by Gomez et al.,12 who showed that a preoperative
cutoff value of 5 was independently associated with
poor disease-free survival after hepatic resection.
Halazun et al.20 expanded this further, showing that
increased preoperative NLR was associated with post-
LT HCC recurrence and recipient death. This finding
was noted in other studies7,18,19,25 in which an ele-
vated pre-LT NLR was independently associated with
cancer relapse and poor overall survival post-LT.
Moreover, in 2 studies, patients with intermediate- or
advanced-stage HCCs who were embolized26 or
treated with sorafenib27 had disease progression and
overall survival that correlated with their baseline
NLRs.
PLR is a less well-studied inflammatory marker that
has been described as a predictor of post-LT tumor
recurrence by Lai et al.18 IBI is a novel inflammatory
score that has been validated as being associated
independently with overall survival in an independent
cohort of 466 HCC patients.15 The GPS and modified
GPS also include CRP and serum albumin and have
both been associated with poor prognosis in different
HCC stages.11
There are potential explanations for why we found
no association of inflammatory markers with HCC
recurrence or survival after LT compared with the pre-
viously published literature. As shown in Table 3, the
mean NLR in our cohort was significantly less than
that in other studies; 12.7% had an NLR >5 com-
pared with 20% in studies by Yoshizumi et al. and Lai
et al. All patients in our cohort were within the Milan
criteria, and the discrepancy between radiological and
histopathological staging was 28%. In previous stud-
ies, fewer patients underwent transplantation within
Milan criteria, and the discrepancy between radiologi-
cal and histopathological evaluation was up to 34%.19
Tumor characteristics in our population were also
more favorable; poor differentiation and microvascular
invasion were found in 8% and 26%, respectively. In
addition, we included only patients who eventually
underwent LT, whereas in the study by Lai et al.18
transplant waiting list dropouts were also evaluated.
Therefore, our population of HCC patients had more
favorable tumor characteristics overall compared with
those in similar studies (Table 3). However, it should
be noted that NLR was not associated with number or
size of HCC lesions. Our time to recurrence after LT
(32 months) was longer than in other studies despite
time on waiting list being significantly shorter.7,18
NLR, PLR, and IBI are ratios that consist of parame-
ters that can easily be affected by infection, chronic
disease, and other similar factors. Cirrhosis is a con-
dition in which cellular immune response is compro-
mised. T-lymphocyte subpopulations are deficient in
cirrhosis, and this deficiency is further worsened
when chronic liver disease is complicated by infec-
tion.28 In addition, bacterial translocation and circu-
lating endotoxin contribute to a proinflammatory
state. Thus, a decreased lymphocyte count or an
infection-induced high neutrophil count may fre-
quently be found in chronic liver disease indepen-
dently of the presence of cancer. CRP, a component of
the IBI score, is a generic marker that can be elevated
in several inflammatory conditions. Serum albumin
may be affected by nutritional status and is associ-
ated with severity of liver disease, regardless of HCC.
Thus, inflammation-based scores and their alterations
could represent several other aspects of disease that
are not necessarily associated with cancer. This con-
clusion is further confirmed by the fact that, even
though NLR, PLR, and IBI were substantially
increased when measured after LT, they still were not
associated with HCC outcome, possibly representing
postsurgical or immunosuppression-related sequelae.
Moreover, inflammatory ratios are calculated from
peripheral blood tests and are far from reflecting the
tumor microenvironment itself. Increased intratu-
moral neutrophils and CD8 T-lymphocyte depletion
are found in HCC tissues and are associated with
HCC progression, but these immune-driven altera-
tions are not reflected directly in peripheral blood.29
In our study, patients who fully responded to neoad-
juvant transarterial embolization with no viable can-
cer in their explanted HCCs had increased NLR and
PLR ratios before LT compared with those who had a
partial or no response to TAE. This elevation was due
predominantly to a significantly higher neutrophil and
platelet count in TAE responders versus nonrespond-
ers, because lymphocytes were equally distributed in
both populations. HCC embolization results in activa-
tion of the host immune system and release of tumor-
specific antigens and proinflammatory cytokines.30
Adequate activation of the host immune response to
tumor may lead to elevation of peripheral inflamma-
tory cells, which could be more profound in those
patients who responded to therapy and achieved an
HCC necrosis. In a study by Huang et al.,30 patients
who had increased NLR post-TAE had better out-
comes, which may reflect the level of tumor necrosis.
Confirmation of this association in further studies is
needed to recommend safely the use of inflammatory
scores to indicate response to TAE and even guide the
decision for repeat TAE sessions.
The only independent predictors of HCC recurrence
in our study were absence of fulfillment of the Milan
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criteria in the explanted liver and the absence of TAE
treatment, factors described previously.9 Tumor size
appears to be the most reproducible predictor of HCC
recurrence post-LT in numerous studies. Molecular
research in intratumoral and peritumoral tissue could
potentially identify novel markers that predict HCC
recurrence. However, the need for biopsy from
tumoral and nontumoral areas is the major limitation
of such methods.31
In conclusion, we failed to demonstrate a significant
association between the inflammatory scores NLR,
PLR, and IBI at various time points and HCC recur-
rence post-LT in patients within the Milan criteria.
Subsequent studies, mostly at the molecular level,
could better clarify the immune alterations taking
place in HCC pre- and posttransplantation and reveal
more specific and accurate serum inflammatory pre-
dictors of HCC recurrence.
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